We've been circling Bristol-Myers Squibb for about six months, watching it trade sideways near multi-year lows while the sell-side slowly capitulates toward a more constructive view. The stock is down roughly 42% from its 2022 peak, yielding above 5%, and trading below 7x forward earnings - in a sector where the average multiple is 15x. On paper, that looks like a screaming value opportunity. Reality is somewhat messier, and that's precisely why the discount exists.
BMY is in the middle of one of the more visible portfolio transitions in Big Pharma. Its legacy blockbusters - Revlimid and Sprycel - are being shredded by generic competition, with Revlimid revenue down 44% year-over-year. Meanwhile, a new generation of growth drugs is accelerating: Camzyos up 89%, Reblozyl up 35%, Krazati up 125%, and the newly approved Cobenfy targeting a $5 billion schizophrenia market. Question isn't whether the growth portfolio will take over - it already has. As of Q1 2025 both sides of the ledger sit at roughly $5.6 billion in quarterly revenue. Question is how quickly investors re-price the story once that transition is undeniable in the numbers.
Add a $40 billion US investment commitment, an $11 billion BioNTech pipeline deal, and a balance sheet generating $13–15 billion in free cash flow annually, and what you have is a company that is actively building toward a 2027–2028 earnings inflection - while paying you a 5%-plus dividend to wait. That combination is rare. We're long here.
Numbers That Matter
Q1 2025 came in well ahead of expectations: revenue of $11.2 billion beat consensus by $490 million, and non-GAAP EPS of $1.80 beat by $0.30 - a 19.9% upside surprise. Guidance was raised for the full year. At the current price, the valuation metrics are historically extreme - and not in the direction the market typically punishes.
Great Rotation: Legacy Erodes, Growth Accelerates
This is the crux of the BMY investment thesis. Markets are pricing in the legacy collapse without adequately crediting the growth acceleration. By Q1 2025, growth drugs matched legacy revenue at ~$5.6 billion each. That crossover is not a projection - it has already occurred. Growth portfolio needs to gain roughly $1.5–$2 billion more per year to fully offset Revlimid's terminal decline, and the trajectory of current approvals suggests that is achievable by 2026–2027.
Cobenfy deserves special mention. Approved in September 2024 for schizophrenia - a disease area without a genuinely new mechanism of action in decades - it generated $27 million in its first partial quarter of commercial launch. Management projects a $5 billion peak revenue opportunity by 2030. That's not a footnote; if it materialises, Cobenfy alone could represent more than 10% of BMY's entire current annual revenue.
A 35% Discount to Its Peer Group
When you line up BMY against the large-cap pharma peer set, the valuation gap is stark. BMY is not trading at a marginal discount - it is trading at levels that imply either zero growth forever or a significant structural deterioration that the fundamental evidence doesn't support.
| Company | Fwd P/E | Div. Yield | FCF Yield | Valuation |
|---|---|---|---|---|
Bristol-Myers Squibb BMY |
6.7x | 5.3% | 13%+ | DEEP VALUE |
Merck & Co. MRK |
11x | 3.3% | 7% | FAIR VALUE |
AbbVie ABBV |
14x | 3.5% | 6% | FAIR VALUE |
Johnson & Johnson JNJ |
14x | 3.3% | 5% | FAIR VALUE |
Healthcare Sector Median |
15x | 2.8% | 4–5% | BENCHMARK |
BMY is currently trading at roughly −1 standard deviation from its own 10-year average P/E multiple. Even applying a conservative 10x multiple to the midpoint of FY2025 guidance ($6.85 EPS) yields a fair-value target north of $68. At the healthcare median of 15x, the implied target exceeds $100. We're not anchoring to either extreme - the market clearly has concerns, which is why the discount exists. But even a partial re-rating to 10–11x P/E, which is still below every peer in the table, places fair value comfortably above our target zone.
Important Disclaimer
This content is for informational and educational purposes only and does not constitute financial advice, investment recommendations, or solicitation to buy or sell any securities. Past performance does not guarantee future results. All investments carry risk, including the possible loss of principal. Bristol-Myers Squibb (NYSE: BMY) is subject to clinical trial risk, regulatory risk, patent cliff risk, generic competition, drug pricing regulation, tariff risk, and general market risk. That BioNTech pipeline deal (BNT327) involves significant clinical and regulatory uncertainty. Dividend payments are not guaranteed and may be reduced or eliminated. All valuation estimates are based on publicly available information and independent analytical models as of June 30, 2025; actual results may differ materially. Always conduct your own due diligence and consult a qualified financial advisor before making any investment decision.